Key result
Dabigatran inhibits cancer cell proliferation and brain extravasation but shows inconsistent overall antimetastatic effects.
Why the study?
Dabigatran's potential anti-metastatic effects in cancer treatment and its impact on cancer cell proliferation and migration remain unclear and inconsistent across cancer types.
Does dabigatran reduce cancer cell proliferation and migration in cancer models?
Systematic Review
Does dabigatran reduce cancer cell proliferation and migration in cancer models?
Answers are grounded in this paper and cite their sources.
Dabigatran demonstrates inconsistent anti-metastatic properties, showing inhibitory effects in certain cancer cell lines and brain metastasis models, but lacking efficacy in triple-negative breast cancer models.
Dabigatran, a direct oral anticoagulant (DOAC), has been investigated for its potential anti-metastatic effects in cancer treatment. This systematic review examines the evidence concerning dabigatran's impact on cancer cell proliferation and migration. Studies suggest that dabigatran inhibits thrombin-induced proliferation in some cancer cell lines, including colorectal cancer (CRC) and oral squamous cell carcinoma (OSCC). However, its effects on metastasis are inconsistent across cancer types. While brain metastasis models show that dabigatran reduces tumor cell extravasation by inhibiting thrombin-mediated clot formation, triple-negative breast cancer (TNBC) models report no significant effect on tumor growth or metastasis.
No takes yet. Share an insight, caveat, or question.
Kazin et al. (2026) conducted a systematic review in Cancer. Dabigatran was evaluated on Cancer cell proliferation and migration. Dabigatran inhibits thrombin-induced proliferation in some cancer cell lines and reduces extravasation in brain metastasis models, but its effects on metastasis are inconsistent across cancer types.
Synapse has enriched 10 related papers. Consider them for comparative context: